Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, announces the appointment of Brendan Buckley as
Poolbeg Pharma PLC (AIM:POLB) Annual Report & AGM Notice
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, confirms that the Company’s
Poolbeg Pharma PLC (AIM:POLB) Results for the year ended 31 December 2022
Significant milestones reached, well capitalised and positioned for future growth
Poolbeg Pharma PLC (AIM:POLB) POLB 001 patent portfolio strengthened
POLB 001 patent portfolio strengthened through granting of US patent
Poolbeg Pharma Plc (AIM:POLB) Positive Results from POLB 001 LPS Human Challenge Trial
Strong potential for POLB 001 to be a blockbuster treatment for severe influenza
As UK food prices rise to a new record high, household grocery bills increase by £788
After signs that food inflation has passed its peak in January, shoppers are now facing the largest increase in grocery bills ever recorded.
Poolbeg Pharma PLC (AIM:POLB) Strategic expansion of POLB 001 into oncology
Complements strong initial data from LPS challenge trial and is in line with stated objective at IPO to expand POLB 001 to additional indications.
Poolbeg Pharma PLC (AIM:POLB) Positive Initial Data Analysis in POLB 001 Trial
Early data readout indicates a successful LPS human challenge trial
Poolbeg Pharma PLC (AIM:POLB) identifies novel RSV drug candidates
Poolbeg identifies new potential drug candidates for Respiratory Syncytial Virus infections as part of Artificial Intelligence Programme
Poolbeg Pharma PLC (AIM:POLB) Metabolic diseases oral delivery licence signed
Poolbeg exclusively licences innovative oral delivery technology for metabolic syndrome related diseases
Poolbeg Pharma PLC (AIM:POLB) POLB 001 LPS human challenge trial completed
POLB 001 LPS human challenge clinical trial successfully completed